Wockhardt Ltd.
WOCKPHARMA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹825.84.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%4.0%
- ✓Low debt (D/E < 0.5)0.42x
- ✕Positive free cash flow
- ✓Revenue growth > 10%26%
- –Earnings growing
- ✕Net margin ≥ 10%6.3%
- ✓Current ratio > 1.51.66
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.22
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Financially solid — Altman Z 6.22.
Weaknesses
- •Low return on equity (4.0%).
Opportunities
- •Revenue growing (26% YoY).
Threats
- •Rich valuation versus sector peers.
- •Trades ~46% above our estimated fair value.
About Wockhardt Ltd.
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.